Company ProfilePremium

Golik Holdings Limited

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Golik Holdings Limited - Company showcase

Year Founded & Workforce

1977

1,511 Employees

Golik Holdings Limited logo

Golik Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Golik Holdings Limited Overview

Golik is a family-controlled, Hong Kong-headquartered industrial holding company with two cash-generative legacy franchises and one nascent healthcare bet. Its largest business by revenue is the supply of building construction materials in Hong Kong — ready-mixed concrete, precast products and the distribution and off-site cut-and-bend processing of reinforcing steel — where it has operated for more than four decades. Its higher-margin franchise is steel wire and steel wire rope manufacturing in Tianjin, Heshan and Jiangmen in Mainland China, historically anchored by elevator ropes (the Group describes its Tianjin unit as China's first elevator-rope manufacturer) and increasingly by high-performance lifting ropes sold to global equipment OEMs including Caterpillar. In November 2024 it opened Assure Medical Imaging (AMI), a PET-CT/MRI/CT centre in Tsim Sha Tsui. The Group trades at roughly 0.45x book and ~4.4x earnings with a net cash balance sheet, reflecting its small size, illiquidity, concentration in a contracting Hong Kong construction market, and controlling-family ownership.


Company's own description (paraphrased from AR25 Ann.)

In its FY2025 announcement Golik identifies three core businesses: metal products, building construction materials, and medical imaging services. The metal products business consists mainly of steel wire and steel wire rope products manufactured at three Mainland Chinese locations (Tianjin, Heshan and Jiangmen). The building construction materials business comprises ready-mixed concrete, precast concrete products, and the processing and distribution of construction steel products in Hong Kong. The medical imaging business provides CT, MRI and PET scanning in Hong Kong. Management describes its strategic emphasis as premium products and value-added services in both legacy businesses rather than competing purely on price. A small money-lending operation (Golik Capital Limited, licensed under Hong Kong's Money Lenders Ordinance) lends to business associates referred by Group companies and is reported as "other operation".

Independent characterisation

Golik is best understood as a regional industrial distributor-processor-manufacturer with the following economic structure:

  • Building construction materials (66% of FY2025 external revenue). Fundamentally a volume- and logistics-driven business tied to Hong Kong construction activity. Revenue is recognised on delivery; contracts are typically multi-year supply agreements for specific projects (remaining performance obligations of HK$1,604.4 M at end-FY2025, AR25 Ann.). Gross margin is driven by the spread between contracted selling prices and steel/cement/aggregate input costs; the FY2025 provision for onerous contracts of HK$55.8 M within this segment demonstrates the downside of fixed-price long-dated supply contracts when costs or competitive pricing move adversely. Value-added processing (cut-and-bend rebar) and transportation have been built up as differentiators.

Metal products (33% of FY2025 external revenue): A genuine manufacturing franchise with technical credentials: national-level "single-field manufacturing champion" recognition (2022), participation in drafting ISO 4344:2022 for elevator wire ropes, Tianjin Key Laboratory status, and a High and New Technology Enterprise (HNTE) tax status in Tianjin. The mix is shifting from domestic elevator ropes (structurally challenged by China's property downturn) toward high-performance lifting ropes for construction machinery and export markets (US revenue HK$134.5 M in FY2025, +21.8% YoY).

Medical imaging (1% of FY2025 external revenue): A capital-intensive diversification into Hong Kong private diagnostics, operating a single flagship centre on a referral model centred on local specialist doctors. EBITDA-positive in FY2025 but loss-making after depreciation, and its fixed assets were impaired by HK$15.3 M in FY2025.

Revenue model mix

Revenue type (FY2025, HKD Mn)Amount% of totalSource
Product sales — steel wire / wire rope (incl. residual steel coil processing line item)1,175.932.5%AR25 Ann. note 3
Product sales — concrete products685.919.0%AR25 Ann. note 3
Product sales — construction steel products & processing, other construction products (incl. processing & transport service income, as re-presented in FY2025)1,712.747.4%AR25 Ann. note 3
Service income — medical imaging41.41.1%AR25 Ann. note 3
Interest income — money lending0.3<0.1%AR25 Ann. note 3
Total3,616.1100%—

There is no subscription or licensing revenue. All revenue is recognised at a point in time (FY2025 policy; in FY2024 medical services had been recognised over time). Credit terms are 30–180 days. No single customer exceeded 10% of revenue in any year reviewed.

Value-chain position and customers

BusinessUpstream inputsGolik's roleCustomers / end-markets
Steel wire ropeWire rod (steel), zinc for galvanisingDrawing, galvanising, stranding, closing ropes; R&DElevator OEMs and maintenance companies (China, export); construction machinery OEMs (e.g. Caterpillar); cranes; historically oilfield ropes (per Simply Wall St company profile)
Construction steelRebar from mills/tradersStockholding, distribution, off-site cut-and-bend processing, deliveryHong Kong main contractors and subcontractors on public and private projects
ConcreteCement, aggregates, admixturesBatching, delivery of ready-mixed concrete; precast productsHong Kong contractors; historically Macau projects
Medical imagingImaging equipment (PET-CT, MRI, CT, ultrasound, mammography, DEXA, X-ray), radiologistsDiagnostic imaging, reportingPatients referred by specialist doctors; insurers (collaboration under development)

Strategy

Stated strategy themes (paraphrased from FY2023–FY2025 announcements)

  1. Prudent operation and quality over scale. In FY2023 management articulated a principle of "prudent operation", prioritising operational efficiency and value-added service over volume; in FY2024 it described a "seeking progress while maintaining stability" approach with lean operations.

  2. Premium products and value-added services. FY2025 strategy centres on premium products and value-added services across both the Mainland wire rope business and the Hong Kong building materials business, explicitly avoiding pure price competition.

  3. Mix shift to high-performance wire ropes and exports. Promotion of high-performance elevator ropes to maintenance and export markets (Southeast Asia) and expansion of high-performance lifting ropes; withdrawal from markets where elevator rope prices fell below cost (H1 2025).

  4. Diversification into healthcare. Establishment of AMI as a new long-term operating business; FY2023 outlook flagged exploring "new and high-quality investment opportunities".

  5. Balance-sheet conservatism. Deleveraging and internal funding of capex.

Initiative register (last 24 months and relevant prior)

InitiativeTimingDetailStatusSource
Assure Medical Imaging (AMI)Invested 2024; launched Nov 2024One-stop imaging centre (PET-CT, MRI, CT etc.) in TST; referral model built around local specialistsRevenue HK$41.4 M FY2025; EBITDA positive; PPE impaired HK$15.3 MAR24 Ann.; AR25 Ann.
AMI operational optimisation & insurer partnershipsH2 2025 onwardImprove throughput; expand collaborations with insurance providers; explore new business developmentOngoing; counterparties not disclosedIR25 Ann.
Market exit — sub-cost elevator rope marketsH1 2025Withdrawal from certain loss-making elevator rope marketsExecutedIR25 Ann.
Export push — Southeast AsiaFY2024 onwardHigh-performance steel wire products to Indonesia, Vietnam and wider SE AsiaOngoingAR24 Ann.
Product innovation investmentFY2025 onwardFurther investment in wire rope innovation and market expansion to consolidate leadership in domestic high-performance segmentOngoing; spend not disclosedIR25 Ann.
New RMC production lineQ1 2023Capacity expansion for Hong Kong ready-mixed concreteCompletedAR22 Ann.
Share option scheme renewal14 Jun 2024Incentive frameworkAdopted; no grants evidentAR24 Ann.
ESG reporting expansionFY2025ESG boundary extended to all Hong Kong operations; first Scope 3 disclosure; qualitative climate-risk assessmentCompletedFY2025 AR summary (sustainabilityreports.com)

Medium-term targets / guidance

Golik provides no quantitative financial targets or guidance. FY2026 qualitative outlook (AR25 Ann.): operating environment expected to remain challenging and uncertain, with downward pressure from competition and uncertainty over exports of certain products to the US; management intends to keep implementing its premium-products strategy to maintain stable performance. Cost programmes with numeric targets: none disclosed.

Products & Services

Golik does not publish product price lists or SKU-level revenue. The catalogue below is compiled from results announcements, annual-report business profiles and third-party company profiles.

Metal products segment

Product lineDescription & capabilitiesTarget customerStatus / latest data pointPricing model
Elevator wire ropesSteel wire ropes for traction elevators; Tianjin unit described as China's first elevator rope maker; Group drafted ISO 4344:2022Elevator OEMs (new installations), maintenance/modernisation market, exportVolume flat in FY2025 but profit contribution declined; certain loss-making markets exited in H1 2025 (IR25 Ann.)Contract/tender pricing; not disclosed
High-performance elevator wire ropesPremium elevator ropes promoted to maintenance and export marketsMaintenance companies; Southeast Asia (Indonesia, Vietnam cited)Management "ramped up promotion" in FY2024 (AR24 Ann.)—
High-performance lifting wire ropesRopes for cranes and construction machinery, developed principally in TianjinConstruction-machinery OEMs (Caterpillar named), crane makers, exportVolume and profit up moderately in FY2025; Caterpillar Supplier Excellence Recognition FY2024 and FY2025—
Galvanised steel wireGalvanised wire production line (pictured in AR21/AR22 business profile)Internal use and external wire customersOngoing—
Crane and oilfield ropesListed in third-party profiles (Simply Wall St)Crane operators, oil & gas——
Pre-stressed (PC) steel strandHistorically produced by Tianjin Golik – The First PC Steel Strand; supplied Three Gorges, Xiaolangdi, Qinshan nuclear plantInfrastructure contractorsCurrent status not disclosed in recent filings—
Steel coil processingSteel coil centres in Guangdong (Dongguan)Manufacturers in Pearl River DeltaDisposed 30 Jul 2021; residual business closed in FY2023—

Building construction materials segment

Product lineDescriptionTarget customerFY2025 revenue (HKD Mn)Notes
Ready-mixed concreteProduced at Hong Kong concrete batching plants (Siu Ho Wan, Lantau historically cited; additional line Q1 2023)Contractors on public works and private developmentsIncluded in concrete products 685.9Concrete revenue grew from 382.3 (FY2021) to 718.3 (FY2024)
Precast concrete productsPrecast elementsContractorsIncluded in concrete products—
Reinforcing steel distributionStockholding and delivery of rebar; Golik Steel described historically as one of Hong Kong's largest rebar suppliersContractorsIncluded in construction steel 1712.7Exposed to steel price volatility
Off-site cut-and-bend processingPrefabricated cut and bent rebar delivered to site; described as widely recognised in the industry and generating returns from FY2023Contractors seeking labour savingsProcessing income 83.9 in FY2024 (last separately disclosed)Value-added differentiator
Decoiling centreRebar decoiling (per third-party profile)Contractors——
Transportation servicesDelivery servicesContractors66.7 in FY2024 (last separately disclosed)—

Medical imaging services segment

ServiceEquipmentTarget customerLaunchNotes
Assure Medical Imaging (AMI) flagship centre, Tsim Sha TsuiPET-CT, MRI, CT, ultrasound, mammography, bone density scanning, X-rayPatients referred by local specialist doctors; insurers; health-check clientsOfficial launch Nov 2024FY2025 revenue HK$41.4 M; segment loss HK$11.6 M; positive EBITDA; PPE impairment HK$15.3 M

Other

ServiceDetail
Golik Capital Limited — money lendingInstalment loans with collateral (HK$3.3 M at 2.46–3.68% p.a.) and one personally guaranteed loan (HK$0.55 M, fully impaired) at end-FY2025 (AR25 Ann.)

Financial Narrative

All figures HK$ M from audited annual results announcements (AR22 Ann. for FY2021–22; AR23 Ann.; AR24 Ann.; AR25 Ann.). EBIT is defined by the analyst as profit before tax + finance costs − share of results of associate/JV (calc.). EBITDA adds depreciation of PPE and right-of-use assets (post-HKFRS 16; calc.). No amortisation of intangibles is reported.

Income statement

Notes: Diluted EPS equals basic — no potential ordinary shares outstanding in any year. FY2021 includes HK$101.9 M gain on disposal of subsidiaries (pre-tax; HK$5.25 M related tax). FY2021 DPS = interim 2.0 + final 3.0 + special 5.0. FY2025 includes HK$15.3 M PPE impairment and HK$55.8 M onerous-contract provision.

Adjusted view (calc.).

Margins (calc.)

Revenue CAGR FY2021–FY2025 (calc.): −2.8% p.a. (HK$4,053.9 M → HK$3,616.1 M). Excluding the steel coil business disposed in 2021 the underlying trend is flatter, but a like-for-like split is not disclosed.

Commentary. The five-year profile shows three phases. FY2021–22 (COVID & steel-price volatility): revenue peaked at HK$4.27 bn in FY2022, but gross margin troughed at 10.6% as volatile steel prices and Hong Kong's fifth COVID wave hit, and attributable profit fell 62% (also lapping the FY2021 disposal gain). FY2023 (re-opening): margin recovery to 15.1% as Hong Kong construction re-accelerated and cut-and-bend processing scaled; attributable profit +84%. FY2024–25 (deliberate de-scaling): revenue fell 17% in FY2024 as Hong Kong deliveries dropped, but gross margin rose to 18.8–19.2% via mix (wire rope exports, value-added services) and price discipline. Administrative expenses rose 18.5% in FY2025 (to HK$240.2 M), reflecting AMI's first full year. Finance costs fell 59% from FY2023 to FY2025 as bank debt was cut by HK$461 M. The FY2025 effective tax rate rose to 18.7% on Mainland under-provisions (HK$4.4 M) and higher Hong Kong taxable profits.

Interim trend

H1 2023–H1 2025 per interim announcements. H1 2026 figures are derived, not filed values: calculated as SA/S&P trailing-twelve-month figures to 30 Jun 2026 (revenue HK$3,375 M; gross profit HK$666.5 M; net income HK$152.25 M) minus FY2025 plus H1 2025. They imply H1 2026 revenue −13% YoY with attributable profit roughly flat; verify against the H1 2026 interim announcement on HKEXnews.

Balance sheet

Notes: Goodwill/intangibles — none presented on the face of the consolidated statement of financial position in any year (reported as zero above on that basis). FY2023 trade payables include bills payable. Company-reported net gearing (borrowings less cash ÷ total equity): 0.44 (FY21), 0.55 (FY22), 0.18 (FY23), −0.04 (FY24), −0.22 (FY25). FY2025 also carries a new HK$55.8 M provision for onerous contracts (current liability).

Commentary. The balance sheet has been transformed: gross bank debt has fallen 64% from its FY2022 peak (HK$1,250.2 M → HK$444.8 M) while cash rose to HK$805.6 M, swinging the Group from net debt of HK$708.7 M to net cash of HK$360.8 M. The deleveraging was funded by working-capital release (inventories −35% from FY2022; receivables lower in FY2024) and retained earnings, as the dividend payout has stayed at ~25%. Almost all bank debt is short-term (94% current at FY2025), typical of Hong Kong trade-finance and revolving facilities, which creates refinancing dependence but is now more than covered by cash. Equity has compounded at ~6% a year since FY2022 with no share issuance or buybacks.

Cash flow

Source: dividend notes in results announcements; "no purchase, sale or redemption of listed securities" statements in each year.

The consolidated cash-flow statement appears only in the full annual reports (not in the results announcements retrieved). Aggregator figures (SA/S&P show FY2025 "free cash flow" of HK$1,536 M, i.e. 42% of revenue) are implausible against a HK$170.9 M profit and HK$91.9 M net debt reduction, and almost certainly gross up trade-finance loan flows; they are therefore not relied upon. As a proxy, contracted capital commitments were HK$8.3 M at end-FY2025 (FY2024: HK$2.3 M; FY2023: HK$86.1 M, the latter associated with the AMI build-out), indicating a low-capex run-rate. Cash rose by HK$206.1 M in FY2025 while bank debt fell HK$91.9 M and dividends of HK$37.3 M were paid, implying strong internal cash generation of the order of HK$300 M+ before financing (calc., indicative only).

Ratios (calc.)

FY2021 ROE and ROIC are inflated by the HK$101.9 M disposal gain; ex-gain ROIC ≈7.2%. Invested capital = total equity + bank borrowings + lease liabilities − cash.

Commentary. Returns have normalised at a low-double-digit level (ROE ~10–12%, ROIC ~12–13%) — respectable for a commodity-adjacent distributor, and achieved with a now-overcapitalised balance sheet (cash = 28% of total assets). The cash conversion cycle has shortened by ~27 days since FY2021, mainly through longer supplier credit (DPO 11 → 32 days). The rise in receivables over 120 days (HK$66.7 M at FY2025 vs HK$25.5 M at FY2024) is a watch-point for credit quality given contractor distress in Hong Kong.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsKey products/services

Metal products

Steel wire & wire rope plants in Tianjin, Heshan, Jiangmen

Elevator wire ropes; high-performance lifting ropes; galvanised steel wire; (historically steel coil processing and PC strand)

Building construction materials

Hong Kong operations

Ready-mixed concrete; precast concrete; rebar distribution; cut-and-bend processing; transportation

Medical imaging services

Assure Medical Imaging, Tsim Sha Tsui

PET-CT, MRI, CT, ultrasound, mammography, bone densitometry, X-ray

Other operation (non-reportable)

Golik Capital Limited

Money lending (loan book HK$3.9 M gross at end-FY2025)

Revenue by Segment

SegmentFY2021FY2022FY2023FY2024FY2025

Metal products revenue (HKD Mn)

1,618.41,222.31,172.31,090.41,179.4

Building construction materials revenue (HKD Mn)

2,441.63,051.92,976.72,354.42,398.7

Medical imaging services revenue (HKD Mn)

0004.241.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment

SegmentFY2021FY2022FY2023FY2024FY2025

Metal products segment result (HKD Mn)

122.278.983.7121.1138.8

Building construction materials segment result (HKD Mn)

67.285.2165.4151.7145.3

Results by Segment (FY2024–FY2025)

SegmentFY2024FY2025

Medical imaging segment result (HKD Mn)

-15.8-11.6

Segment Margins & Growth (%)

SegmentFY2021FY2022FY2023FY2024FY2025

Metal products margin (%)

7.66.57.111.111.8

Building construction materials margin (%)

2.82.85.66.46.1

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2022FY2023FY2024FY2025

Metal products revenue growth (%)

-24.5-4.1-7.08.2

Building construction materials revenue growth (%)

25.0-2.5-20.91.9

Metal products share of external revenue (%)

28.528.231.532.5

Building construction materials share of external revenue (%)

71.571.868.366.3

Results by Segment (Half-Yearly)

SegmentH1 2024H1 2025

Metal products revenue (HKD Mn)

519.2556.5

Building construction materials revenue (HKD Mn)

1,211.51,248.1

Metal products result (HKD Mn)

44.268.4

Building construction materials result (HKD Mn)

78.471.3

Other operations result incl. medical (HKD Mn)

-3.6-7.8

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (HKD Mn)

4,053.94,271.24,145.73,445.83,616.1

Cost of sales (HKD Mn)

3,538.93,818.33,520.42,796.72,920.8

Gross profit (HKD Mn)

515.0452.9625.2649.1695.3

Selling & distribution costs (HKD Mn)

131.7139.9172.0168.2179.8

Administrative expenses (HKD Mn)

196.1159.9185.0202.8240.2

Finance costs (HKD Mn)

27.141.552.934.321.7

EBIT, calc. (HKD Mn)

276.4146.9230.7240.8229.9

D&A, PPE + ROU (HKD Mn)

94.481.275.082.891.5

EBITDA, calc. (HKD Mn)

370.8228.1305.7323.6321.3

Profit before tax (HKD Mn)

249.1106.2178.8208.3210.2

Income tax (HKD Mn)

27.615.617.927.839.3

Profit for the year (HKD Mn)

221.590.5160.9180.4170.9

Profit attributable to owners (HKD Mn)

197.675.7138.9158.1151.2

Basic EPS (HK cents)

34.4013.1724.1927.5326.33

Diluted EPS (HK cents)

34.4013.1724.1927.5326.33

Dividend per share incl. special (HK cents)

10.05.06.06.56.5

Income Statement

MetricFY2021FY2022FY2023FY2024FY2025

EBIT excl. disposal gain and PPE impairment (HKD Mn)

174.5146.9230.7240.8245.1

Profit before tax excl. disposal gain and PPE impairment (HKD Mn)

147.2106.2178.8208.3225.5

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

12.710.615.118.819.2

EBIT margin (%)

6.83.45.67.06.4

EBITDA margin (%)

9.15.37.49.48.9

Pre-tax margin (%)

6.12.54.36.05.8

Net margin, attributable (%)

4.91.83.44.64.2

Effective tax rate (%)

11.114.710.013.418.7

Income Statement (Half-Yearly)

MetricH1 2023H1 2024H1 2025H1 2026

Revenue (HKD Mn)

1,961.11,728.71,818.11,577.0

Gross profit (HKD Mn)

282.6321.1355.9327.1

Profit attributable to owners (HKD Mn)

63.161.670.671.6

Balance Sheet and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (HKD Mn)

3,147.83,035.32,919.32,711.92,856.1

Property, plant & equipment (HKD Mn)

491.6490.7465.0524.3471.8

Right-of-use assets (HKD Mn)

280.8226.4161.2160.0153.9

Inventories (HKD Mn)

760.9785.0590.5605.8509.6

Trade & bills receivables, net (HKD Mn)

813.6883.3924.6724.8814.6

Cash & cash equivalents (HKD Mn)

672.7541.6652.1599.5805.6

Bank borrowings — current (HKD Mn)

1,245.81,250.2906.1498.7416.8

Bank borrowings — non-current (HKD Mn)

00038.028.0

Total bank borrowings (HKD Mn)

1,245.81,250.2906.1536.7444.8

Lease liabilities, total (HKD Mn)

283.5233.1167.1169.5165.6

Net debt, bank borrowings less cash (HKD Mn)

573.1708.7254.0-62.8-360.8

Net debt incl. leases (HKD Mn)

856.6941.8421.1106.7-195.2

Trade payables (HKD Mn)

103.4130.6261.5275.6253.2

Equity attributable to owners (HKD Mn)

1,193.91,169.71,268.51,382.21,509.4

Non-controlling interests (HKD Mn)

113.2108.4118.6130.9142.3

Total equity (HKD Mn)

1,307.11,278.11,387.11,513.11,651.8

Goodwill & intangibles (HKD Mn)

00000

Working capital, CA less CL (HKD Mn)

763.2756.6910.31,022.11,195.2

Book value per share, attributable (HKD)

2.082.042.212.412.63

Dividends & Capital Returns

MetricFY2021FY2022FY2023FY2024FY2025

Dividends paid to owners of the Company (HKD Mn)

31.657.431.634.537.3

Share buybacks (HKD Mn)

00000

Change in total bank borrowings (HKD Mn)

—4.5-344.1-369.4-91.9

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE, attributable on average equity (%)

16.66.411.411.910.5

ROA, profit for year on average total assets (%)

7.02.95.46.46.1

ROIC, NOPAT on year-end invested capital (%)

11.45.611.512.912.8

Current ratio (x)

1.491.491.672.042.19

Bank debt to equity (x)

0.950.980.650.350.27

Net debt to EBITDA (x)

1.553.110.83-0.19-1.12

Interest coverage, EBIT to finance costs (x)

10.23.54.47.010.6

Asset turnover (x)

1.291.381.391.221.30

Days sales outstanding (days)

73.375.581.476.882.2

Days inventory outstanding (days)

78.575.061.279.163.7

Days payables outstanding (days)

10.712.527.136.031.6

Cash conversion cycle (days)

141.1138.0115.5119.9114.3

Revenue by Region

RegionFY2021FY2022FY2023FY2024FY2025

Hong Kong revenue (HKD Mn)

2,310.02,899.32,893.82,350.82,440.5

Mainland China revenue (HKD Mn)

1,513.91,069.41,054.3911.4965.2

Rest of world incl. Macau and US (HKD Mn)

230.0302.4197.6183.5210.4

Revenue by Region (FY2024–FY2025)

RegionFY2024FY2025

United States revenue (HKD Mn)

110.5134.5

Others incl. Macau (HKD Mn)

73.175.9

Region Margins & Growth (%)

RegionFY2023FY2024FY2025

Hong Kong growth (%)

-0.2-18.83.8

Mainland China growth (%)

-1.4-13.55.9

Rest of world growth (%)

-34.7-7.114.7

Segment Overview — Metal products

SegmentHong KongMainland ChinaUnited StatesOthersTotal

Metal products

11.2955.0134.575.21,175.9

Building construction materials

2,387.710.100.72,398.6

Medical imaging

41.400041.4

Locations

LocationFY2024FY2025

Hong Kong non-current assets (HKD Mn)

340.5303.5

Mainland China non-current assets (HKD Mn)

345.1331.3

Data Point Details

Data pointValueSource

Last close

HK$1.17 (9 Oct 2026)

SA

52-week change

≈+20%

SA (as of 1 Oct 2026)

50-day / 200-day moving average

HK$1.16 / HK$1.17

SA

Beta (5Y)

0.40

SA

Implied price, Mar 2025

≈HK$0.81 (market cap HK$465.2 M ÷ shares)

TipRanks (calc.)

Implied price, Jun 2025

≈HK$0.95 (market cap HK$545.7 M)

TipRanks (calc.)

Valuation Multiples

MultipleGolikBasis

Market capitalisation

HK$672.0 M

574.38 M shares

P/E (FY2025)

4.4x

EPS HK26.33 cents

P/E (TTM to Jun 2026)

4.4x

SA

P/B

0.45x

FY2025 attributable equity HK$1,509.4 M (SA quotes 0.39x on a different equity basis)

EV (incl. NCI and leases, FY2025 balance sheet)

≈HK$619 M

672.0 + 142.3 + 444.8 + 165.6 − 805.6

EV/EBITDA (FY2025)

≈1.9x

EBITDA HK$321.3 M (SA: 1.83x on TTM)

EV/Sales (FY2025)

≈0.17x

—

Dividend yield (FY2025 DPS)

5.6%

HK6.5 cents

Dividend yield (TTM DPS, derived)

≈6.0%

HK7.0 cents

Dividend

DividendFY2021FY2022FY2023FY2024FY2025

Interim dividend (HK cents)

2.02.02.52.52.5

Final dividend (HK cents)

3.03.03.54.04.0

Special dividend (HK cents)

5.00000

Total dividend (HK cents)

10.05.06.06.56.5

Payout ratio, total DPS to basic EPS (%)

29.138.024.823.624.7

Capital Markets

ItemStatus

Buyback authorisation

General repurchase mandate renewed at each AGM (e.g. 13 Jun 2025); no repurchases executed FY2021–FY2025

Credit ratings (Moody's/S&P/Fitch)

Not rated

Debt maturity (FY2025)

Bank borrowings: HK$416.8 M due within one year; HK$28.0 M due after one year. Lease liabilities: HK$27.4 M current; HK$138.2 M non-current

Liquidity

Very thin trading; free float ≈36%

Analyst Conclusions

Management guidance

Qualitative only (AR25 Ann., 27 Mar 2026): 2026 expected to remain challenging and uncertain, with downward pressure from competition and uncertainty over US exports; strategy remains premium products and high-value-added services to keep performance stable. H1 2025 language was "cautiously optimistic" for the full year, which proved broadly accurate (FY2025 profit before impairment rose).

Consensus

No analyst coverage; no consensus estimates exist.

Bull case

  1. Deep value with net cash: at ~HK$672 M market cap, the Group trades at ~0.45x book and ~1.9x EV/EBITDA, with net bank cash of HK$360.8 M equal to ~54% of market value; even modest re-rating or higher payouts could drive returns.

  2. Earnings mix improving: the wire rope business now generates more segment profit than Hong Kong building materials, at nearly double the margin (11.8% vs 6.1%), supported by OEM relationships and exports.

  3. Cyclical optionality in Hong Kong: a growing backlog (HK$1.6 bn, +23%) and the Northern Metropolis pipeline could lift volumes from a depressed base while Golik's balance sheet lets it survive competitor attrition.

Bear case

  1. Hong Kong demand trough may be long: management itself sees no improvement and warns of price wars; the HK$55.8 M onerous-contract provision shows backlog quality can deteriorate.

  2. Tariff exposure in the growth engine: US revenue (HK$134.5 M, +22%) is the fastest-growing market and explicitly at risk from geopolitics.

  3. Capital allocation and governance discount: a controlling family, thin liquidity, ~25% payout and a sub-scale, impaired healthcare venture suggest cash may continue to accumulate rather than be returned, sustaining the discount.

Catalysts & monitorables (next 12 months)

  • H1 2026 interim report: confirm derived revenue decline (~−13%), segment mix, onerous-contract utilisation, and interim DPS (~HK3.0 cents?).

  • US tariff decisions affecting Chinese wire rope exports.

  • Hong Kong public-works funding approvals and Northern Metropolis tender flow.

  • AMI utilisation, insurer partnerships, any further impairment.

  • Aged receivables >120 days and ECL charges.

  • Any special dividend or buyback execution given the HK$805.6 M cash pile.

  • FY2026 annual results (expected late March 2027).

Analyst verdict

Golik Holdings is a financially robust but strategically constrained small-cap whose equity story has quietly changed. Five years ago it was a leveraged Hong Kong building-materials distributor with a Chinese steel-processing appendage, carrying net bank debt of HK$573 M and earning 3–4% net margins in good years. Today it is a net-cash industrial whose most valuable asset is arguably a technically credentialed wire rope franchise — ISO standard author, national manufacturing champion, Caterpillar-recognised supplier — earning double-digit segment margins, bolted to a Hong Kong construction-materials business that is now managed for margin and cash rather than volume.

The financial record supports the "quality improvement" reading: gross margin has nearly doubled since FY2022, ROIC has stabilised near 13%, finance costs have more than halved and equity has compounded without dilution. Yet the top line remains under pressure (FY2021–25 revenue CAGR −2.8%, with H1 2026 apparently down again), both core end-markets are cyclically or structurally weak, the newest growth vector (US exports) is politically exposed, and the healthcare diversification has started by impairing assets.

The valuation — roughly 4.4x earnings, 0.45x book and under 2x EV/EBITDA — already discounts much of this. The binding constraint on shareholder returns is not operations but capital allocation: with cash equivalent to more than half the market capitalisation and a payout ratio near 25%, minority investors depend on the controlling family's willingness to distribute or deploy excess capital productively. Absent that, the discount can persist indefinitely given negligible liquidity and no research coverage.

Key upside triggers would be a higher payout or buyback, a visible Hong Kong order upturn, or evidence that AMI can earn its cost of capital; key downside triggers are US tariff escalation and further onerous-contract or credit losses.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenure / key datesCommitteesNotes

Mr. PANG Tak Chung, MH

Executive Director, Chairman

—

Chairman of Nomination Committee; member of Remuneration Committee since 15 Feb 2023

Co-CODM; MH (Medal of Honour) recipient.

Mr. HO Wai Yu, Sammy

Executive Director, Vice Chairman; Company Secretary

——

FCCA, MHKCS, MHKSI; co-CODM

Ms. PANG Wan Ping

Executive Director; Chief Executive Officer

CEO since 1 Jan 2022

Nomination Committee since 30 Jun 2025

—

Mr. PANG Chi To

Executive Director

Appointed 1 Aug 2021

——

Mr. HAI Tuen Tai, Freddie

Independent Non-executive Director

Appointed 16 Jun 2021

Audit, Remuneration, Nomination

—

Mr. LUK Kam Fan, Jimmy

Independent Non-executive Director

Appointed c.

Audit, Remuneration, Nomination

—

Mr. LINN Hon Chung, Ambrose

Independent Non-executive Director

Appointed 1 Feb 2023

Audit, Remuneration, Nomination

—

Directors' Remuneration

AttributeStatus

Board size

7 (4 executive, 3 independent non-executive)

Independence

43% — meets the HKEX minimum of one-third

Chair/CEO separation

Separate individuals (Chairman Pang Tak Chung; CEO Pang Wan Ping), but both from the controlling family

Gender diversity

1 of 7 directors female (14%)

Audit Committee

3 INEDs; established 5 Jan 1999

Remuneration Committee

Chairman plus 3 INEDs

Nomination Committee

Chaired by Chairman; CEO and 3 INEDs

CG Code compliance

Full compliance stated for FY2024 and FY2025; FY2022 and FY2023 deviations from code provision C.1.6 (two INEDs absent from AGMs)

Share option scheme

Adopted 14 Jun 2024 (replacing 2014 scheme); no options outstanding (no dilutive potential shares)

Board & Management Changes

DateChangeContext

27 Mar 2021

Mr. Lo Yip Tong (INED) resigned

Board refresh

16 Jun 2021

Mr. Hai Tuen Tai appointed INED

Replacement

1 Jul 2021

Mr. Lau Ngai Fai (ED) resigned

—

1 Aug 2021

Mr. Pang Chi To appointed ED

Next-generation family succession

1 Jan 2022

Ms. Pang Wan Ping appointed CEO

Succession

1 Feb 2023

Mr. Linn Hon Chung appointed INED

Board refresh ahead of long-tenured INED retirements

9 Jun 2023

Mr. Yu Kwok Kan and Mr. Chan Yat Yan (INEDs) retired

Long-tenure INEDs replaced

30 Jun 2025

Ms. Pang Wan Ping joined Nomination Committee

Likely to meet HKEX gender-diversity expectations for committees (analyst inference)

Major Shareholders

Holder categoryStakeSource

Insiders / substantial shareholders (aggregate)

≈63.65%

SA/S&P

Free float

≈208.8 M shares (≈36.4%)

SA/S&P

Institutional ownership

Not publicly disclosed / negligible per aggregators

SA/S&P ("n/a")

Competitive Landscape

Competitors by Segment

SegmentCompetitorType / listingRelative positioning

Wire rope (global)

Bekaert (Bridon-Bekaert Ropes Group)

Euronext Brussels

Global leader in steel wire and ropes; far larger scale

Wire rope (global)

WireCo WorldGroup

Private (US)

Major global lifting and mining rope supplier

Wire rope (global)

Teufelberger

Private (Austria)

Premium crane and elevator ropes

Wire rope (global)

Pfeifer Group

Private (Germany)

Crane ropes and lifting solutions

Wire rope (global)

Gustav Wolf

Private (Germany)

Elevator rope specialist

Wire rope (Asia)

Kiswire

Private (Korea)

Large Asian wire and rope maker

Wire rope (Asia)

Tokyo Rope Mfg.

TSE

Japanese elevator/crane ropes

Wire rope (Asia)

Usha Martin

NSE/BSE India

Integrated wire rope producer, export-oriented

Wire rope (China)

Guizhou Wire Rope

SSE (600992)

State-linked domestic rope producer

Wire rope (China)

Jiangsu Fasten / Langshan wire rope makers

Domestic

Large-volume domestic competitors in steel wire products

HK concrete

Alliance Construction Materials (CK Infrastructure-affiliated)

Private JV

Major HK aggregates/concrete supplier

HK concrete

K. Wah Construction Materials

Part of K. Wah International (0173.HK)

Established HK concrete and precast supplier

HK concrete / cement

China Resources Building Materials

1313.HK

Cement and concrete in South China and HK

HK rebar

Shiu Wing Steel

Private

HK's local steel mill and rebar supplier

HK medical imaging

Private hospitals (e.g. Hong Kong Sanatorium & Hospital, CUHK Medical Centre) and independent imaging centres

Private

Established referral networks and hospital integration

HK medical imaging

Mainland-linked health-check providers operating in HK

Various

Low-priced packages and digital marketing (cited by Golik as pricing pressure)

Competitor Detail

MetricGolik (FY2025)

Revenue

HK$3,616.1 M

Revenue growth

+4.9%

Gross margin

19.2%

EBIT margin

6.4% (calc.)

Recent Developments

Litigation, regulatory actions, layoffs or guidance revisions: none identified in the window.

Company Snapshot

$464.2M

Revenue

1,511

Employees

1977

Founded

Hamilton HM, Bermuda

Headquarters

SWOT Analysis

Strengths

  • Net cash balance sheet: cash HK$805.6 M vs bank debt HK$444.8 M at FY2025; net gearing −0.22 (AR25 Ann.).
  • Rising profitability despite lower revenue: gross margin up from 10.6% (FY2022) to 19.2% (FY2025) while revenue fell 15%.
  • Wire rope franchise quality: metal segment margin 11.8% in FY2025 (from 6.5% in FY2022); segment profit +15% in FY2025.
  • OEM endorsement: Caterpillar Supplier Excellence Recognition in FY2024 and FY2025.
  • Standards and technology credentials: ISO 4344:2022 drafting; national single-field champion (2022); HNTE renewed from 2025.
  • Contracted visibility: building materials remaining performance obligations HK$1,604.4 M at FY2025, up 23% from HK$1,309.2 M.

Weaknesses

  • Geographic concentration: Hong Kong = 67.5% of FY2025 revenue in a market management describes as contracting.
  • Elevator rope margin erosion: management reports further erosion in FY2025 and exits from sub-cost markets in H1 2025.
  • Onerous contracts: HK$55.8 M provision in FY2025 reveals exposure on fixed-price supply contracts.
  • Medical imaging under-earning: HK$11.6 M segment loss and HK$15.3 M PPE impairment in FY2025 on HK$41.4 M revenue.
  • Short-dated funding: 94% of bank borrowings current (HK$416.8 M of HK$444.8 M).
  • Governance optics: four of seven directors executive; CEO, Chairman and another ED from the same family; 63.65% insider ownership; INED share only 43%.

Opportunities

  • Northern Metropolis and other long-cycle Hong Kong public works expected to revive demand in two to three years (AR24 Ann.).
  • Export expansion: US revenue +21.8% in FY2025; Southeast Asia (Indonesia, Vietnam) cited as growth markets.
  • Elevator maintenance/modernisation demand in China's ageing installed base as offset to new-build weakness.
  • AMI scale-up via insurer partnerships and higher throughput (IR25 Ann.).
  • Capital allocation: HK$805.6 M cash could fund higher dividends, buybacks (market cap only ~HK$672 M) or bolt-on acquisitions.
  • Consolidation: closures of long-established contractors (AR24 Ann.) may remove weaker competitors over time.

Threats

  • US tariffs/geopolitics affecting exports of certain products — explicitly flagged in FY2026 outlook.
  • Hong Kong construction downturn persisting — management projects challenging trend for the foreseeable future (AR25 Ann.).
  • China property slump — elevator production down ~25% in FY2024.
  • Contractor credit risk: receivables >120 days rose to HK$66.7 M (FY2025) from HK$25.5 M (FY2024); ECL allowance on trade receivables HK$64.3 M.
  • Mainland medical providers' price competition in Hong Kong imaging.
  • Steel price volatility — FY2022 gross margin collapsed to 10.6% partly on steel cost swings.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
13 Jun 2025AGM — all resolutions passed (accounts, FY2024 final dividend HK4.0 cents, director re-elections, issue/repurchase mandates) TipRanks / HKEX poll resultsRoutine; repurchase mandate renewed but unused
30 Jun 2025CEO Pang Wan Ping appointed to Nomination Committee 2025 Interim ReportGovernance
24 Jul 2025FY2024 final dividend HK4.0 cents paid AR24 Ann.Shareholder return
6 Aug 2025Board meeting date notice for interim results HKEX noticeRoutine
27 Aug 2025H1 2025 results: revenue +5% to HK$1,818.1 M; attributable profit +15% to HK$70.6 M; interim DPS HK2.5 cents IR25 Ann.Metal segment profit +55%; building materials −9%
27 Aug 2025Disclosure of exit from certain sub-cost elevator rope markets IR25 Ann.Margin protection
27 Aug 2025AMI reported positive EBITDA variance within first six months; plan to expand insurer collaborations IR25 Ann.Healthcare build-out
26 Sep 20252025 Interim Report published HKEXnewsRoutine
2 Oct 2025Ex-dividend for 2025 interim dividend TipRanks—
24 Oct 20252025 interim dividend HK2.5 cents paid IR25 Ann.—
FY2025Tianjin wire rope company: second consecutive Caterpillar Supplier Excellence Recognition AR25 Ann.OEM relationship validated
FY2025Tianjin subsidiary HNTE status renewed (three years from 2025) AR25 Ann.Tax rate 15% maintained
27 Mar 2026FY2025 results: revenue +5% to HK$3,616.1 M; attributable profit −4% to HK$151.2 M; net cash HK$360.8 M AR25 Ann.Steady earnings; balance sheet strengthening
27 Mar 2026HK$15.3 M impairment of medical imaging PPE AR25 Ann.Signals pressure on AMI returns
27 Mar 2026HK$55.8 M provision for onerous contracts in building materials AR25 Ann.Long-dated supply contracts now loss-making
27 Mar 2026FY2026 outlook flags US export uncertainty from geopolitical factors AR25 Ann.Tariff risk to fastest-growing market
27 Mar 2026Final DPS HK4.0 cents proposed (total FY2025 HK6.5 cents) AR25 Ann.Payout ~25%
Apr 2026 (est.)FY2025 Annual Report with ESG disclosures published (152 pages); first Scope 3 reporting sustainabilityreports.com summaryESG maturity
12 Jun 2026FY2025 AGM (scheduled) AR25 Ann.Routine
23 Jul 2026FY2025 final dividend payment (scheduled) AR25 Ann.—
Aug 2026Top-line pressure, margins resilient
30 Sep 2026Possible dividend increase
9 Oct 2026Share price HK$1.17; 52-week change ≈+20% SARe-rating from very low base

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

8 charts
Income Statement: Revenue & Gross Profit: Revenue fell from HKD 4,053.9 Mn in FY2021 to HKD 3,616.1 Mn in FY2025.
Golik Holdings Limited — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2021FY2022FY2023FY2024FY2025
Revenue4,053.94,271.24,145.73,445.83,616.1
Cost of sales3,538.93,818.33,520.42,796.72,920.8
Gross profit515452.9625.2649.1695.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Golik Holdings — Annual Results for the year ended 31 Dec 2025 (HKEXnews, 27 Mar 2026) (www1.hkexnews.hk)
  2. Golik Holdings — Annual Results for the year ended 31 Dec 2024 (26 Mar 2025) (www1.hkexnews.hk)
  3. Golik Holdings — Annual Results for the year ended 31 Dec 2023 (28 Mar 2024) (www1.hkexnews.hk)
  4. Golik Holdings — Annual Results for the year ended 31 Dec 2022 (30 Mar 2023) (www1.hkexnews.hk)
  5. Golik Holdings — Interim Results for the six months ended 30 Jun 2025 (27 Aug 2025) (www1.hkexnews.hk)
  6. Golik Holdings — 2025 Interim Report (hkexnews.hk)
  7. Golik Holdings — 2024 Interim Report (moomoo mirror) (newsfile.moomoo.com)
  8. Golik Holdings — 2021, 2022 and 2023 Interim Reports (HKEXnews corporate information pages)
  9. Golik Holdings — Positive Profit Alerts (18 Mar 2022; 15 Mar 2024) and Profit Warning (16 Mar 2023), HKEXnews
  10. Golik Holdings — 2021, 2022, 2023 Annual Reports (HKEXnews); 2001, 2004, 2006 Annual Reports (historical business profiles)
  11. StockAnalysis.com (S&P Global Market Intelligence data) — statistics and income statement for HKG:1118 (accessed Oct 2026)
  12. TipRanks — Golik announcements (board meetings, AGM results, interim dividend 2025)
  13. Simply Wall St — SEHK:1118 company profile
  14. Sustainabilityreports.com — Golik Holdings 2025 Annual Report summary (ESG metrics)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.